Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat plus rituximab in relapsed or refractory follicular lymphoma
CTR20240881Phase 3Active
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abexinostat, rituximab in follicular lymphoma (FL), sponsored by Xynomic Pharmaceuticals. Started Mar 2024; status: active.
02
Drugs
abexinostatrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20240881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240881.